Physician profile
Gwen H Dalphon
NPI 1245574250
$116,437.43
in general payments reported to CMS, 2019-2025
31 companies · $52K in 2025
The $52K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,612 · 2022: $8,540 · 2023: $20K · 2024: $35K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Consulting Fee: $16K · Food and Beverage: $16K · Travel and Lodging: $9,509 · Education: $306 · Honoraria: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $63,805.00 |
| Consulting Fee | $16,211.00 |
| Food and Beverage | $16,148.81 |
| Travel and Lodging | $9,508.98 |
| Education | $306.22 |
| Honoraria | $305.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $66,374.69 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $27,284.47 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $3,884.45 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Eli Lilly and Company | $3,750.00 | 2025 | Ebglyss |
| Regeneron Healthcare Solutions, INC. | $3,296.86 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,823.14 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Journey Medical Corporation | $1,667.44 | 2022-2025 | |
| Abbvie INC. | $1,458.60 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,111.02 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Ucb, INC. | $788.66 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $661.35 | 2021-2025 | |
| Pfizer INC. | $556.33 | 2021-2025 | |
| Genzyme Corporation | $478.53 | 2021-2025 | |
| Dermavant Sciences, INC. | $446.94 | 2023 | Vtama |
| Amgen INC. | $400.63 | 2021-2025 | Otezla, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $372.84 | 2021-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $372.64 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $370.40 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $243.24 | 2021-2025 | Siliq, Cabtreo |
| Janssen Scientific Affairs, LLC | $219.55 | 2022 | |
| Almirall LLC | $199.40 | 2021-2025 | Klisyri |
| Organon LLC | $196.72 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.07 | 2022-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Genentech USA, INC. | $63.45 | 2023-2024 | Erivedge |
| Regeneron Pharmaceuticals, INC. | $60.00 | 2024 | Dupixent |
| Epi Health, LLC | $53.26 | 2021-2022 | |
| Verrica Pharmaceuticals INC. | $24.16 | 2024 | Ycanth |
| Dermira, INC. | $19.74 | 2021 | |
| Biofrontera INC. | $16.03 | 2021 | |
| Vyne Pharmaceuticals INC. | $14.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gwen Dalphon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.